Zhongguancun: Its subsidiary Shandong Huasu Amber acid Metoprolol API has been approved for listing.

On the evening of August 22, Zhongguancun announced that its subsidiary, Shandong Huasu Pharmaceutical Co., Ltd., has recently passed the technical review of the drug evaluation center of the National Medical Products Administration for the "metoprolol succinate raw material," and has obtained the "Chemical Raw Material Market Application Approval Notice" issued by the National Medical Products Administration. The raw material has been approved for marketing, providing a stable source of raw materials for the company's current research on metoprolol succinate sustained-release capsules, which will have a positive impact on the company's business performance.